This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Isis Pharmaceuticals Initiates Phase 1b/2a Study Of ISIS-SMNRx In Patients With Spinal Muscular Atrophy

CARLSBAD, Calif., Nov. 1, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 1b/2a study evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA).  SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.

"SMA is a devastating disease that leads to the premature loss of nerve cells in the spinal cord necessary for normal muscle function.  Children with SMA generally appear normal at birth, with muscle wasting and atrophy developing as early as a few months after birth.  In the most severe form of the disease, children never sit or walk and have a significantly shortened lifespan.  Although the genetic cause of SMA is well understood, the identification of an effective drug that will halt or improve the disease process has not occurred," said Richard Finkel, M.D., chief, division of neurology, Nemours Children's Hospital, Orlando, Florida.  "ISIS-SMNRx is specifically designed to intervene in the nerve cell's RNA machinery by improving splicing efficiency.  This results in an increase in the production of a normal protein, SMN, which is deficient in children with SMA.  This promising new approach could for the first time have a profound effect in children with SMA."

The Phase 1b/2a study of ISIS-SMNRx is a multiple-dose, dose-escalation study designed to assess the safety, tolerability and pharmacokinetic profile of the drug in children with SMA between the ages of 2-15 who are medically stable.   In the ongoing Phase 1 study in children with SMA, all patients have completed dosing and ISIS-SMNRx was well tolerated as a single dose administered directly into the cerebral spinal fluid.  In the Phase 1b/2a study, children with SMA will receive either two or three doses of ISIS-SMNRx during the course of the study.  Data from this study will also provide information to aid in identifying the dose for the Phase 2/3 registration-directed program in patients with SMA.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs